Primary endpoint was met with no factor VIII inhibitors detected, confirming the safety profile of efanesoctocog alfa in previously treated patients under 12 years of age The completion of XTEND-Kids represents the final milestone needed for regulatory submission in the EU STOCKHOLM,…